FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791812865> ?p ?o ?g. }

• W2791812865 endingPage "474" @default.
• W2791812865 startingPage "467" @default.
• W2791812865 abstract "Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.Multicentre prospective observational study of consecutive SLE patients receiving belimumab for at least 3 months, due to active disease refractory to at least one conventional immunosuppressant. Disease activity, including the recently defined lupus low disease activity state (LLDAS) and remission (clinical SLEDAI-2K = 0), accrual of organ damage, flares and side effects were documented.Ninety-one patients were included [94.5% women, mean (SD) age 45.9 (12.5) years]. Most frequent manifestations were arthritis (76.7%), rash (72.5%), serologic activity (low C3/C4 and/or high anti-dsDNA; 54.9%), hair loss (47.2%) and mucosal ulcers (27.5%). Median (range) duration of treatment was 10.5 (3.0-42.1) months. Belimumab significantly decreased average SLEDAI-2K, physician global assessment (PGA) and daily prednisone dose over time, as early as 3 months after initiation, with over 20% of patients discontinuing corticosteroids. Although reduction in clinical (i.e., excluding serology) SLEDAI-2K was more pronounced in patients who were serologically active (from 8 to 1.5 at 12 months) as compared to serologically inactive (from 6 to 4) at baseline, attainment of LLDAS did not differ between the two groups and was reached by more than 40% of completer patients after 9-12 months. In addition, the number of flares and severe flares was reduced by 62% and 50%, respectively, during the first 12 months of treatment. Twenty patients (22.0%) discontinued treatment due to inadequate response and two due to side effects potentially related to the drug.In real-life, belimumab is efficacious in achieving low disease activity in over 40% of unselected patients, in combination with reduction of corticosteroid dosage and number of flares. Both serologically active and inactive patients respond to the drug." @default.
• W2791812865 created "2018-03-29" @default.
• W2791812865 creator A5007341235 @default.
• W2791812865 creator A5013415342 @default.
• W2791812865 creator A5018328341 @default.
• W2791812865 creator A5021706761 @default.
• W2791812865 creator A5025805658 @default.
• W2791812865 creator A5027237191 @default.
• W2791812865 creator A5027706354 @default.
• W2791812865 creator A5032650280 @default.
• W2791812865 creator A5032947271 @default.
• W2791812865 creator A5034748610 @default.
• W2791812865 creator A5039759199 @default.
• W2791812865 creator A5040513014 @default.
• W2791812865 creator A5041004610 @default.
• W2791812865 creator A5041092312 @default.
• W2791812865 creator A5048007142 @default.
• W2791812865 creator A5057315838 @default.
• W2791812865 creator A5059609848 @default.
• W2791812865 creator A5059943791 @default.
• W2791812865 creator A5062248231 @default.
• W2791812865 creator A5071905620 @default.
• W2791812865 creator A5073747255 @default.
• W2791812865 creator A5083865505 @default.
• W2791812865 creator A5086939776 @default.
• W2791812865 creator A5090569471 @default.
• W2791812865 date "2018-12-01" @default.
• W2791812865 modified "2023-10-18" @default.
• W2791812865 title "Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study" @default.
• W2791812865 cites W1964173805 @default.
• W2791812865 cites W2018939131 @default.
• W2791812865 cites W2033418370 @default.
• W2791812865 cites W2070527591 @default.
• W2791812865 cites W2091675224 @default.
• W2791812865 cites W2096286605 @default.
• W2791812865 cites W2107216509 @default.
• W2791812865 cites W2108905161 @default.
• W2791812865 cites W2113864921 @default.
• W2791812865 cites W2119296184 @default.
• W2791812865 cites W2122679394 @default.
• W2791812865 cites W2131366312 @default.
• W2791812865 cites W2131457901 @default.
• W2791812865 cites W2131723901 @default.
• W2791812865 cites W2136149088 @default.
• W2791812865 cites W2154001276 @default.
• W2791812865 cites W2156027405 @default.
• W2791812865 cites W2158263012 @default.
• W2791812865 cites W2159860161 @default.
• W2791812865 cites W2199189793 @default.
• W2791812865 cites W2255119417 @default.
• W2791812865 cites W2288194547 @default.
• W2791812865 cites W2292748966 @default.
• W2791812865 cites W2338584698 @default.
• W2791812865 cites W2399507807 @default.
• W2791812865 cites W2524018888 @default.
• W2791812865 cites W2549420521 @default.
• W2791812865 cites W2587800318 @default.
• W2791812865 cites W2593714154 @default.
• W2791812865 cites W2625419804 @default.
• W2791812865 cites W2664231786 @default.
• W2791812865 cites W2756377741 @default.
• W2791812865 cites W2787827666 @default.
• W2791812865 doi "https://doi.org/10.1016/j.semarthrit.2018.02.014" @default.
• W2791812865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29555348" @default.
• W2791812865 hasPublicationYear "2018" @default.
• W2791812865 type Work @default.
• W2791812865 sameAs 2791812865 @default.
• W2791812865 citedByCount "53" @default.
• W2791812865 countsByYear W27918128652018 @default.
• W2791812865 countsByYear W27918128652019 @default.
• W2791812865 countsByYear W27918128652020 @default.
• W2791812865 countsByYear W27918128652021 @default.
• W2791812865 countsByYear W27918128652022 @default.
• W2791812865 countsByYear W27918128652023 @default.
• W2791812865 crossrefType "journal-article" @default.
• W2791812865 hasAuthorship W2791812865A5007341235 @default.
• W2791812865 hasAuthorship W2791812865A5013415342 @default.
• W2791812865 hasAuthorship W2791812865A5018328341 @default.
• W2791812865 hasAuthorship W2791812865A5021706761 @default.
• W2791812865 hasAuthorship W2791812865A5025805658 @default.
• W2791812865 hasAuthorship W2791812865A5027237191 @default.
• W2791812865 hasAuthorship W2791812865A5027706354 @default.
• W2791812865 hasAuthorship W2791812865A5032650280 @default.
• W2791812865 hasAuthorship W2791812865A5032947271 @default.
• W2791812865 hasAuthorship W2791812865A5034748610 @default.
• W2791812865 hasAuthorship W2791812865A5039759199 @default.
• W2791812865 hasAuthorship W2791812865A5040513014 @default.
• W2791812865 hasAuthorship W2791812865A5041004610 @default.
• W2791812865 hasAuthorship W2791812865A5041092312 @default.
• W2791812865 hasAuthorship W2791812865A5048007142 @default.
• W2791812865 hasAuthorship W2791812865A5057315838 @default.
• W2791812865 hasAuthorship W2791812865A5059609848 @default.
• W2791812865 hasAuthorship W2791812865A5059943791 @default.
• W2791812865 hasAuthorship W2791812865A5062248231 @default.
• W2791812865 hasAuthorship W2791812865A5071905620 @default.
• W2791812865 hasAuthorship W2791812865A5073747255 @default.
• W2791812865 hasAuthorship W2791812865A5083865505 @default.
• W2791812865 hasAuthorship W2791812865A5086939776 @default.

• next